Actively Recruiting

Age: 18Years - 65Years
All Genders
ID06550622

Improved Sensitivity Detection of Serum HBsAg in Chronic Hepatitis B Patients Achieving Functional Cure and Its Association With HBsAg Reversion

Led by Huashan Hospital · Updated on 2024-08-13

300

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This research aims to understand the rate at which hepatitis B surface antigen (HBsAg) returns in chronic hepatitis B patients who have tested negative for HBsAg after treatment. The study compares a new, more sensitive HBsAg NEXT assay with the current ARCHITECT HBsAg assay to measure HBsAg reversion at 48 weeks after stopping treatment. It focuses on patients who have achieved functional cure under interferon therapy and completed consolidation therapy.

CONDITIONS

Brief Title

Improved Sensitivity Detection of Serum HBsAg and HBsAg Reversion

Who Can Participate

Age: 18Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 65 years
  • HBsAg-negative by Abbott's HBsAg Test and HBeAg-negative
  • Have serum specimens retained at baseline and at 48 weeks off treatment follow-up
  • Willing to follow up regularly for 1 year
Not Eligible

You will not qualify if you...

  • Patients with hepatitis B cirrhosis in compensated or decompensated stages
  • Patients with combined infections such as HAV, HCV, HDV, HEV, HIV, or other chronic liver diseases
  • Patients with primary hepatocellular carcinoma or high AFP levels suggesting malignancy
  • Patients with other malignant tumors (unless cured)
  • Patients with severe or uncontrolled diseases
  • Participants in other clinical studies
  • Patients deemed unsuitable by the investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Long-term Monitoring

Duration - 48 weeks

Participants who have discontinued therapy after achieving HBsAg loss are observed to monitor HBsAg reversion and related outcomes.

Regular follow-up visits over 48 weeks

Trial Site Locations

Total: 1 location

1

Fahong Li

Shanghai, Shanghai Municipality, China, 200040

Actively Recruiting

Loading map...

Research Team

F

Fahong Li

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

2

Similar Trials

"Real-life" Cohort Study on Patients With Chronic Hepatitis ...

Hepatitis B, Chronic

Actively Recruiting

6 locations

A Real-world Study of Staging and Grading of Clinical Immune...

Hepatitis B, Chronic

Actively Recruiting

5 locations

Double Plasma Molecular Adsorption System With Sequential Lo...

Hepatitis B, Chronic

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here